Paulette Barahona

Ms. Paulette Barahona

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
CMChelsea Mayoh
Chelsea Mayoh
JMJie Mao
Jie Mao
JXJinhan Xie
Jinhan Xie
GTGabor Tax
Gabor Tax
SCShu-Oi Chow
Shu-Oi Chow
EDEmmy Dolman
Emmy Dolman
For one-third of patients with pediatric cancer enrolled in precision medicine programs, molecular profiling does not result in a therapeutic recommendation. To identify potential strategies for treating these high-risk pediatric patients, we performed in vitro screening of 125 patient-derived samples against a library of 126 anticancer drugs. Tumor cell expansion did not influence drug responses, and 82% of the screens on expanded tumor cells were completed while the patients were still under clinical care. High-throughput drug screening (HTS) confirmed known associations between activating genomic alterations in NTRK, BRAF, and ALK and responses to matching targeted drugs. The in vitro results were further validated in patient-derived xenograft models in vivo and were consistent with clinical responses in treated patients. In addition, effective combinations could be predicted by correlating sensitivity profiles between drugs. Furthermore, molecular integration with HTS identified biomarkers of sensitivity to WEE1 and MEK inhibition. Incorporating HTS into precision medicine programs is a powerful tool to accelerate the improved identification of effective biomarker-driven therapeutic strategies for treating high-risk pediatric cancers. Significance: Integrating HTS with molecular profiling is a powerful tool for expanding precision medicine to support drug treatment recommendations and broaden the therapeutic options available to high-risk pediatric cancers.

12 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
JWJacqueline P. Whitehouse
Jacqueline P. Whitehouse
MHMeegan Howlett
Meegan Howlett
HHHilary Hii
Hilary Hii
CMChelsea Mayoh
Chelsea Mayoh
MWMarie Wong
Marie Wong
RERaelene Endersby
Raelene Endersby
Radiation-induced glioma (RIG) is a highly aggressive brain cancer arising as a consequence of radiation therapy. We report a case of RIG that arose in the brain stem following treatment for paediatric medulloblastoma, and the development and characterisation of a matched orthotopic patient-derived xenograft (PDX) model (TK-RIG915). Patient and PDX tumours were analysed using DNA methylation profiling, whole genome sequencing (WGS) and RNA sequencing. While initially thought to be a diffuse intrinsic pontine glioma (DIPG) based on disease location, results from methylation profiling and WGS were not consistent with this diagnosis. Furthermore, clustering analyses based on RNA expression suggested the tumours were distinct from primary DIPG. Additional gene expression analysis demonstrated concordance with a published RIG expression profile. Multiple genetic alterations that enhance PI3K/AKT and Ras/Raf/MEK/ERK signalling were discovered in TK-RIG915 including an activating mutation in PIK3CA, upregulation of PDGFRA and AKT2, inactivating mutations in NF1, and a gain-of-function mutation in PTPN11. Additionally, deletion of CDKN2A/B, increased IDH1 expression, and decreased ARID1A expression were observed. Detection of phosphorylated S6, 4EBP1 and ERK via immunohistochemistry confirmed PI3K pathway and ERK activation. Here, we report one of the first PDX models for RIG, which recapitulates the patient disease and is molecularly distinct from primary brain stem glioma. Genetic interrogation of this model has enabled the identification of potential therapeutic vulnerabilities in this currently incurable disease.

13 February 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
NFNoemi A. Fuentes-Bolanos
Noemi A. Fuentes-Bolanos
ECEliza K. Courtney
Eliza K. Courtney
CMChelsea Mayoh
Chelsea Mayoh
MWMeera Warby
Meera Warby
LLLoretta Lau
Loretta Lau
DZDavid Ziegler
David Ziegler
Purpose: The role of germline predisposition in pediatric cancer is increasingly recognized. However, the optimal approach to identifying cancer predisposing germline pathogenic variants (GPV) in children, and even the prevalence of GPVs among children with cancer, remain unclear. We examined GPV prevalence and diagnostic yield of different test approaches within a national pediatric precision oncology program. Experimental Design: We performed prospective rapid-turnaround whole-genome and -transcriptome profiling of 496 consecutively recruited children with poor-prognosis cancer to identify genetic variants linked to cancer risk. Results: Integration of tumor and germline molecular profiling identified GPVs in 15.5% of patients, an incremental GPV yield of 7.9% above that detected by standard care. Although the cancer type was outside the recognized phenotypic spectrum for 43.7% of reported GPVs, 63.2% of these were clinically actionable. Integrated germline-tumor analysis increased the GPV detection rate by 8.5%, informed germline interpretation in 14.3% of patients with GPVs, and provided biological insight into tumor etiology, together highlighting the value of integrated analyses. Cascade testing in first-degree relatives confirmed that the GPV was de novo in 21% of tested families. Within inherited GPVs (73.9%), 47.8% had direct implications for risk management recommendations in the relevant parent. Conclusions: Our findings establish the clinical benefit and feasibility of integrated tumor–germline whole-genome screening to detect GPVs in children with poor-prognosis cancers and their first-degree relatives.

9 August 2024 in medRxiv
Verified
Preprint
Open access
PDF file
NFNoemi A Fuentes-Bolanos
Noemi A Fuentes-Bolanos
ECEliza Courtney
Eliza Courtney
CMChelsea Mayoh
Chelsea Mayoh
MWMeera Warby
Meera Warby
LLLoretta Lau
Loretta Lau
DZDavid Ziegler
David Ziegler
Germline predisposition has a significant role in paediatric cancer. However, the optimal approach to identifying cancer-causing germline pathogenic variants (GPV) in children, and even the prevalence of GPV among children with cancer, remain unclear. Here we report our findings from a comprehensive survey of GPV in 496 children with poor-prognosis cancer. By integrating tumour and germline molecular profiling we identified GPV in 15.5% of patients, 48.1% of whom had not met clinical genetic testing criteria. Although the cancer type was outside the recognised phenotypic spectrum for 43.7% of reported GPV, 63.2% of these were clinically actionable for cancer risk. Integrated germline-tumour analysis increased the GPV detection rate by 8.5%, and informed germline interpretation in 14.3% of patients with GPV, highlighting the value of integrated analyses. Our findings establish the benefit of broad integrated tumour-germline screening, over phenotype-guided testing, to detect GPV in children with poor prognosis cancers.